CYCLACEL PHARMACEUTICALS INC's ticker is CYCC and the CUSIP is 23254L603. A total of 24 filers reported holding CYCLACEL PHARMACEUTICALS INC in Q2 2022. The put-call ratio across all filers is - and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $7,380 | -39.8% | 20,806 | 0.0% | 0.00% | – |
| Q2 2023 | $12,257 | +3.3% | 20,806 | 0.0% | 0.00% | – |
| Q1 2023 | $11,870 | -14.5% | 20,806 | 0.0% | 0.00% | – |
| Q4 2022 | $13,878 | -53.7% | 20,806 | 0.0% | 0.00% | – |
| Q3 2022 | $30,000 | -9.1% | 20,806 | -32.5% | 0.00% | – |
| Q2 2022 | $33,000 | +6.5% | 30,806 | +207.9% | 0.00% | – |
| Q1 2022 | $31,000 | -27.9% | 10,006 | -9.1% | 0.00% | – |
| Q4 2021 | $43,000 | -18.9% | 11,006 | +10.0% | 0.00% | – |
| Q3 2021 | $53,000 | -85.1% | 10,006 | -83.3% | 0.00% | -100.0% |
| Q2 2021 | $355,000 | -19.5% | 60,006 | -3.2% | 0.00% | 0.0% |
| Q1 2021 | $441,000 | -0.9% | 62,006 | +8.8% | 0.00% | 0.0% |
| Q4 2020 | $445,000 | +166.5% | 57,006 | +24.6% | 0.00% | – |
| Q3 2020 | $167,000 | +16.8% | 45,756 | +48.8% | 0.00% | – |
| Q2 2020 | $143,000 | – | 30,756 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| SILVERARC CAPITAL MANAGEMENT, LLC | 388,632 | $2,048,000 | 1.16% |
| Tri Locum Partners LP | 522,943 | $2,756,000 | 1.10% |
| Sio Capital Management, LLC | 422,598 | $2,227,000 | 0.71% |
| Affinity Asset Advisors, LLC | 400,000 | $2,108,000 | 0.53% |
| SPHERA FUNDS MANAGEMENT LTD. | 508,322 | $2,679,000 | 0.22% |
| Ikarian Capital, LLC | 99,422 | $524,000 | 0.04% |
| PURA VIDA INVESTMENTS, LLC | 105,141 | $554,000 | 0.02% |
| Virtu Financial LLC | 20,029 | $106,000 | 0.01% |
| NEXT Financial Group, Inc | 14,752 | $77,000 | 0.01% |
| Schonfeld Strategic Advisors LLC | 103,925 | $548,000 | 0.01% |